Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CTL019
Financials
Cancer activist concerned about Novartis' CAR-T pricing
Cancer patient and advocate David Mitchell visited Novartis to discuss what a fair price might be for its CAR-T treatment, but he left disappointed.
Arlene Weintraub
Aug 30, 2017 9:00am
Cosentyx sales double, aiding Novartis Q2 earnings beat
Jul 18, 2017 11:13am
Oxford BioMedica and Novartis build on cell therapy supply deal
Jul 6, 2017 8:53am
How will Novartis price CAR-T? Here are some clues
Jun 8, 2017 10:17am
